Cash and Short Term Investments (Annual) Chart

View Cash and Short Term Investments (Annual) for NVO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Annual) Chart
Start Trial

Historical Cash and Short Term Investments (Annual) Data

View and export this data back to 1980. Start Trial.
Date Value
December 31, 2025 4.240B
December 31, 2024 3.653B
December 31, 2023 4.480B
December 31, 2022 3.383B
December 31, 2021 2.673B
December 31, 2020 2.097B
December 31, 2019 2.325B
December 31, 2018 2.396B
December 31, 2017 3.412B
December 31, 2016 3.011B
December 31, 2015 3.023B
December 31, 2014 2.589B
December 31, 2013 2.953B
December 31, 2012 3.010B
December 31, 2011 3.065B
December 31, 2010 2.890B
December 31, 2009 2.473B
December 31, 2008 1.897B
December 31, 2007 1.447B
December 31, 2006 902.69M
December 31, 2005 794.66M
December 31, 2004 723.43M
December 31, 2003 523.45M
Date Value
December 31, 2002 245.54M
December 31, 2001 366.69M
December 31, 2000 483.65M
December 31, 1999 608.00M
December 31, 1998 426.90M
December 31, 1997 590.30M
December 31, 1996 474.66M
December 31, 1995 672.50M
December 31, 1994 667.98M
December 31, 1993 524.63M
December 31, 1992 623.29M
December 31, 1991 739.57M
December 31, 1990 514.85M
December 31, 1989 447.28M
December 31, 1988 365.59M
December 31, 1987 334.00M
December 31, 1986 271.22M
December 31, 1985 234.86M
December 31, 1984 189.65M
December 31, 1983 178.78M
December 31, 1982 86.25M
December 31, 1981 108.06M
December 31, 1980 42.25M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Annual) Range, Past 5 Years

View Cash and Short Term Investments (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Annual) Benchmarks

View Cash and Short Term Investments (Annual) Benchmarks
Start Trial
AstraZeneca PLC 5.741B
Johnson & Johnson 20.10B
Eli Lilly & Co. 7.268B
Merck & Co., Inc. 14.69B
Novartis AG 11.59B